Focus on aripiprazole

References

• Yokoi F, Grunder G, Biziere K, Stephane M, Dogan AS, Dannals RF, Ravert H, Suri A, Bramer S, Wong, DF. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C] raclopride. Neuropsychopharmacol 2002;27: 248–59
   Google Scholar
• Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 2002;441(3):137–40
   PubMed Web of Science ®Google Scholar
• Mallikaarjun S, Salazar DE, Bramer SL. The pharmacokinetics, tolerability and safety of aripiprazole following single and multiple oral dose administration. Int J Neuropsychopharm 2000;3(Suppl 1):S123
   Google Scholar
• Mallikaarjun S, Riesgo Y, Salazar D, Bramer S, Xie J, Weston IE. Time of dosing and food effect on aripiprazole pharmacokinetics. Poster presentation ECNP, Prague, 2003
   Google Scholar
• Burris KD, Molski TF, Xu C, Ryan E, Tattori K, Kikuchi T, Yocca FD, Molinoff PB. Aripiprazole, a novel antipsychotic is a high affinity partial agonist at human D2 receptors. J Pharmacol Expl Ther 2002;302;381–9
   PubMed Web of Science ®Google Scholar
• Matsubayashi H, Amano T, Sasa M. Inhibition by aripiprazole of dopaminergic inputs to striatal neurons from substantia nigra. Psychopharmacol 1999;146(2):139–43
   Web of Science ®Google Scholar
• Carson W, Saha AR, Iwamoto T et al. Meta-analysis of prolactin effects with aripiprazole. Int J Neuropsychopharmacol. 2002;5(Suppl 1):S186
   Google Scholar
• Inoue A, Miki S, Seto M, Kikuchi T, Morita S, Ueda H, Misu Y, Nakata Y. Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol 1997;321(1):105–11
   PubMed Web of Science ®Google Scholar
• Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, Oshiro Y, Morita S. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Expl Ther 1995;274(1):329–36
   Google Scholar
• de Deyn P, Jeste D, Auby P, Goyvaerts H, Brede C, Schneider L, Mintzer J, Iwamoto I, Carson W. Arpiprazole treatment for psychosis in patients with Alzheimer’s disease. Poster presentation, ECNP, Prague, 2003
   Google Scholar
• Bourin M, Auby P, Swanmik R, Marcus R, McQuafe R. Aripirazole vs haloperidol for maintained treatment effect in acute mania. Poster presentation, ECNP, Prague, 2003
   Google Scholar
• Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psych 2002;63(9):763–71
   Web of Science ®Google Scholar
• Daniel DG, Saha AR, Ingenito G, Carson WH, Dunbar GC. Aripiprazole, a novel antipsychotic: overview of a phase II study result. Int. J Neuropsychopharm 2000;3\(Suppl. 1):S157
   Google Scholar
• Sugiyama A, Satoh Y, Hashimoto K. In vivo canine model comparison of cardiohemodynamic and electrophysiological effects of a new antipsychotic drug aripiprazole (OPC-14597) to haloperidol. Tox Applied Pharmacol 2001;173(2):120–8
   PubMed Web of Science ®Google Scholar
• Lahti AC, Weiler MA, Corey PK, Lahti RA, Carlsson A, Tamminga CA. Antipsychotic properties of the partial dopamine agonist (–)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in schizophrenia. Biol Psych 1998;43:2–11
   PubMed Web of Science ®Google Scholar
• McQuade RD, Jody DN, Kujawa MJ, Carson WH, Iwamoto T, Archibald DG, Stock, EG. Long-term weight effects of aripiprazole vs olanzapine. Poster presentation at APA, San Francisco, 2003
   Google Scholar
• Stock EG, Archibald DG, Tourkodimitris S, Kujawa MJ, Marcus R, Carson WH. Long-term effects of aripiprazole on affective symptoms of schizophrenia. Poster presentation at APA, San Francisco, 2003
   Google Scholar
• Kostic D, Manos G, Stock EG, Jody DN, Archibald DG, Tourkodimitris S, Marcus R, Iwamoto T, Carson W. Poster presentation, ECNP, Prague, 2003
   Google Scholar
• Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psych 2003;64:1048–56
   Web of Science ®Google Scholar
• Cornblatt B, Kern RS, Carson WH, Dunbar GC, Ali M, Ingenito G, Green MF. An open label comparison of the neurocognitive effects of aripiprazole vs. olanzapine in patients with stable psychosis. Data presented at Mount Sinai Conference on cognition and schizophrenia, British Columbia, Canada, 2001
   Google Scholar
• Kujawa M, Saha A, Ingenito GG, Ali M, Luo X, Archibald DG, Carson WH. Aripiprazole for long-term maintenance treatment of schizophrenia. Poster presentation, APA, Philadelphia, 2002
   Google Scholar
• Kujawa M, Stringfellow J, Hardy S, Ali M, Lam S, Marcus R, Stock E. The efficacy of aripiprazole in patients with schizoaffective disorder. Poster presentation, APA, San Francisco, 2003
   Google Scholar
• Carson WH, Archibald DG, Manos G, Kostic D, Marcus R, Stock EG. Short-term efficacy of aripiprazole on depression/anxiety in schizophrenia. Poster presentation, APA, San Francisco, 2003
   Google Scholar
• Stock EG, Marder SR, Jody DN, Kaplita SB, Saha AR, Carson WH, Torbeyns AF. Plasma lipid levels and glycemic control in long-term treatment with aripiprazole. Poster presentation, ECNP, Prague, 2003
   Google Scholar
• Keck PE, Marcus R, Tourkodimitris S, Ali M, Liebeskind A, Saha A, Ingenito G. A placebo controlled double blind study of the efficacy and safety of aripirazole in patients with acute bipolar mania. Am J Psychiatry 2003;160:1651–8
   PubMed Web of Science ®Google Scholar
• Findling RL, Blumer JL, Kauffman R, Batterson JR, Gilbert DL, Bramer S, Marcus R. Aripirazole in pediatric conduct disorder: a pilot study. Poster presentation, ECNP, Prague, 2003
   Google Scholar
• Casey DE, Carson WH, Saha AR, Liebeskind A, Ali MW, Jody D, Ingenito GG. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacol 2003; April, 391–9
   Google Scholar
• Larson G, Lehrmann J, Berger B, Tsao C, Phillips K. Prior exposure to typical or atypical antipsychotics as a factor of aripiprazole’s effect on weight. Data presented at New Clinical Drug Evaluation Unit 41st annual meeting, Phoenix, Arizona, USA, 2001
   Google Scholar
• Marder, SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, Ali M, Iwamoto T. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizo Res 2003; June, 123–36
   Google Scholar
• Saha AR, Carson WH, Ali MW, Dunbar GC, Ingenito G. Efficacy and safety of aripiprazole and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. W J Biol Psychiat 2001;2\(Suppl. 1):305S
   Google Scholar
• Goodnick PJ, Rodriguez L, Santana O. Antipsychotics: impact on prolactin levels. Expert Opin Pharmacother 2002;3(10):1381–91
   PubMedGoogle Scholar
• Canive JM, Lewine JD, Edgar JC, Davis JT, Miller GA, Torres F, Tuason VB. Spontaneous brain magnetic activity in schizophrenia patients treated with aripiprazole. Psychopharmacol Bull 1998;34(1):101–5
   PubMed Web of Science ®Google Scholar
• Bramer S, Shoaf S, Salazar D, Mallikaarjun S. Lack of effect of renal and hepatic impairment on the pharmacokinetics of aripirazole. Poster presentation, ECNP, Prague, 2003
   Google Scholar